Does the New Deal for Opening Prescription Drug Prices Fail Trump to Be a Drug God

category:Finance
 Does the New Deal for Opening Prescription Drug Prices Fail Trump to Be a Drug God


This is another measure taken by the Trump government to enhance transparency in the whole industry. According to U.S. Health Secretary Azar, transparency can give patients the right to choose. The executive order also requires the Department of Health to take regulatory measures to address unexpected bills, while studying other barriers to transparency in health care costs.

The ideal is beautiful, but in reality there is still a mountain of pharmaceutical manufacturers. Earlier this year, when the Trump government expressed its intention, a number of pharmaceutical companies immediately rose up and filed a lawsuit claiming that requiring them to disclose prices was coercive and violated their right to freedom of expression.

Zhao Heng, a medical expert, said that prescription drugs in the United States are really difficult to manage prices because U.S. law prohibits the government from negotiating prices directly with pharmaceutical companies. Commercial insurance companies can negotiate prices with pharmaceutical companies, but the government does not allow them.

But Trumps fist did not reach the meat. According to an analysis of brand prescription drug prices by the Associated Press, the increase in drug prices from January to July last year was lower than that of the same period last year, but the price increase of pharmaceutical companies was much greater than that of price reduction. By the end of July last year, there were 4412 drugs that had risen in price, while only 46 drugs had fallen in price. The situation this year is not optimistic. From January to July this year, the prices of more than 3,400 prescription drugs have risen, 17% more than about 2,900 in the same period last year. Analysis by Rx Savings Program Inc. shows that the average increase of these drugs is about five times the inflation rate, and the rise of Prozac in the treatment of depression is 879%. For high drug prices, Zhao Heng told Beijing Business Daily that prescription drugs in the United States are priced independently. The rising drug prices are mainly due to the high prices of brand drugs, i.e. new specialty drugs. Pharmaceutical companies use R&D costs as an excuse to obtain high profits. Other generic drugs are difficult to obtain high profits because they have passed the patent period. Now. Source: Guo Chenqi_NBJ9931, Responsible Editor of Beijing Business Daily

But Trumps fist did not reach the meat. According to an analysis of brand prescription drug prices by the Associated Press, the increase in drug prices from January to July last year was lower than that of the same period last year, but the price increase of pharmaceutical companies was much greater than that of price reduction. By the end of July last year, there were 4412 drugs that had risen in price, while only 46 drugs had fallen in price. The situation this year is not optimistic. From January to July this year, the prices of more than 3,400 prescription drugs have risen, 17% more than about 2,900 in the same period last year. Analysis by Rx Savings Program Inc. shows that the average increase of these drugs is about five times the inflation rate, and the rise of Prozac in the treatment of depression is 879%.

For high drug prices, Zhao Heng told Beijing Business Daily that prescription drugs in the United States are priced independently. The rising drug prices are mainly due to the high prices of brand drugs, i.e. new specialty drugs. Pharmaceutical companies use R&D costs as an excuse to obtain high profits. Other generic drugs are difficult to obtain high profits because they have passed the patent period. Now.